In Q2, Rite Aid completed its EnvisionRx acquisition and continued its move toward becoming a retail healthcare company, chairman and CEO John Standley said when announcing the company's quarterly earnings.
Although growth has been high for new specialty and brand-name drugs in the past year, generics continue to be a central part of the U.S. pharmaceutical market.
Symantec has recently reported that three out of five cyber attacks target small and medium-sized businesses, favoring point-of-sale systems at brick and mortar stores.
The hiring comes just months after the retailer tapped former Walmart executives to fill the head merchant and CFO roles at the 389-store retailer.
Kroger will target 12 years of consecutive same-store sales growth when it reports third-quarter results in three months.
A week after suing Albertsons for $1 billion, west coast regional grocer Haggen has filed Chapter 11 and continues to cite Albertsons as the source of its difficulties.
The acquisitions will bring InvaGen’s 32 products and 40 approved abbreviated new drug applications, as well as Exelan’s management team and institutional market under the company’s control.
Pfizer said that the transaction has strengthened the company’s branded and generics portfolio, particularly when it comes to biosimilars.
Fueled in part by increased pharmacy sales, Fred’s reported Thursday that its August sales hit $165.6 million this year, up 12% over August 2014.
Prescription counts decreased a little and pharmacy same-store sales were up in August, according to numbers reported by Rite Aid Thursday.